FY2023 · ended Dec 31, 2023 · Revenue $1.10M, -65.6% YoY · Filed Apr 15, 2025
Matinas Biopharma Holdings, Inc. (MTNB) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $761,000 in cash and investments and $1.4 million in total debt.
Revenue
$1.10M
-65.6% vs prior year
Net income
$-10.35M
+57.3% vs prior year
Operating cash flow (TTM)
$-6.42M
+41.8% vs year-ago TTM
Free cash flow
$-15.50M
+22.7% vs prior year
EPS
$-2.00
+59.8% vs prior year
Dividend per share
None
Shares outstanding
6.41M
+25.9% vs prior year
Net cash
$-592,000
as of Jun 30, 2026
Operating margin
-2168.4%
FY 2023
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MTNB (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bedminster, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1582554
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $1.1M | $3.2M | $33,000 |
| Operating income | -$7.0M | -$24.6M | -$23.8M | -$24.6M | -$24.7M |
| Net income | -$10.3M | -$24.3M | -$22.9M | -$21.0M | -$23.3M |
| Diluted EPS | -$2.00 | -$4.98 | -$5.28 | — | — |
| Operating cash flow | -$7.0M | -$15.9M | -$15.3M | -$19.2M | -$15.2M |
| Free cash flow | — | — | -$15.5M | -$20.0M | -$15.5M |
| Total assets | $7.2M | $12.6M | $25.1M | $44.8M | $61.3M |
| Total liabilities | $2.4M | $5.1M | $5.9M | $8.2M | $8.8M |
| Stockholders' equity | $4.8M | $7.6M | $19.2M | $36.6M | $52.5M |
| Cash and investments | $4.0M | $7.3M | $13.8M | $28.8M | $49.6M |
| Total debt | $1.4M | $2.9M | $3.6M | $4.1M | $4.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Sep 28, 2026 | Sep 25, 2026 |
| 8-K |
Current report
Other events
|
Sep 16, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Listing notice, Other events
|
Sep 4, 2026 | Aug 31, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Agreement ended
|
Jul 24, 2026 | Jul 23, 2026 |
All 570 Matinas Biopharma Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.